{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:18:08Z","timestamp":1791271088944,"version":"4.1.0"},"reference-count":52,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4,15]]},"abstract":"<jats:p>Since the identification of the proteinase-activated receptor (PAR) family as mediators of serine protease activity in the 1990s, there has been tremendous progress in the elucidation of their pathophysiological roles. The development of drugs that target PARs has been the focus of many laboratories for the potential treatment of thrombosis, cancer and other inflammatory diseases. Understanding the mechanisms of PAR activation and G protein signalling pathways evoked in response to the growing list of endogenous proteases has yielded great insight into receptor regulation at the molecular level. This has led to the development of new selective modulators of PAR activity, particularly PAR1. The mixed success of targeting PARs has been best exemplified in the context of inhibiting PAR1 as a new antiplatelet therapy. The development of the competitive PAR1 antagonist, vorapaxar (Zontivity), has clearly shown the value in targeting PAR1 in acute coronary syndrome (ACS); however the severity of associated bleeding with this drug has limited its use in the clinic. Due to the efficacy of thrombin acting via PAR1, strategies to selectively inhibit specific PAR1-mediated G protein signalling pathways or to target the second thrombin platelet receptor, PAR4, are being devised. The rationale behind these alternative approaches is to bias downstream thrombin activity via PARs to allow for inhibition of pro-thrombotic pathways but maintain other pathways that may preserve haemostatic balance and improve bleeding profiles for widespread clinical use. This review summarizes the structural determinants that regulate PARs and the modulators of PAR activity developed to date.<\/jats:p>","DOI":"10.1042\/bst20150282","type":"journal-article","created":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T09:57:10Z","timestamp":1460368630000},"page":"606-612","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Proteinase-activated receptors (PARs) as targets for antiplatelet therapy"],"prefix":"10.1042","volume":"44","author":[{"given":"Margaret","family":"Cunningham","sequence":"first","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"McIntosh","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Bushell","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Sloan","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Plevin","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2016,4,11]]},"reference":[{"key":"2021111818085465100_B1","doi-asserted-by":"crossref","first-page":"C1429","DOI":"10.1152\/ajpcell.1998.274.6.C1429","article-title":"Proteinase-activated receptors: novel mechanisms of signaling by serine proteases","volume":"274","author":"Dery","year":"1998","journal-title":"Am. J. Physiol."},{"key":"2021111818085465100_B2","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"key":"2021111818085465100_B3","doi-asserted-by":"publisher","first-page":"9208","DOI":"10.1073\/pnas.91.20.9208","article-title":"Molecular cloning of a potential proteinase activated receptor","volume":"91","author":"Nystedt","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111818085465100_B4","doi-asserted-by":"publisher","first-page":"6642","DOI":"10.1073\/pnas.95.12.6642","article-title":"Cloning and characterization of human protease-activated receptor 4","volume":"95","author":"Xu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111818085465100_B5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/386502a0","article-title":"Protease-activated receptor 3 is a second thrombin receptor in humans","volume":"386","author":"Ishihara","year":"1997","journal-title":"Nature"},{"key":"2021111818085465100_B6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fendo.2014.00067","article-title":"Biased signaling of protease-activated receptors","volume":"5","author":"Zhao","year":"2014","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2021111818085465100_B7","doi-asserted-by":"publisher","first-page":"e31756","DOI":"10.1371\/journal.pone.0031756","article-title":"The extended cleavage specificity of human thrombin","volume":"7","author":"Gallwitz","year":"2012","journal-title":"PLoS One"},{"key":"2021111818085465100_B8","doi-asserted-by":"publisher","first-page":"8603","DOI":"10.1021\/bi700597p","article-title":"Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site","volume":"46","author":"Nieman","year":"2007","journal-title":"Biochemistry"},{"key":"2021111818085465100_B9","doi-asserted-by":"crossref","first-page":"16977","DOI":"10.1016\/S0021-9258(19)47326-2","article-title":"The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity","volume":"266","author":"Liu","year":"1991","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/35007085","article-title":"PAR3 is a cofactor for PAR4 activation by thrombin","volume":"404","author":"Nakanishi-Matsui","year":"2000","journal-title":"Nature"},{"key":"2021111818085465100_B11","doi-asserted-by":"publisher","first-page":"32553","DOI":"10.1074\/jbc.M113.472373","article-title":"Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by alpha-thrombin","volume":"288","author":"Arachiche","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B12","doi-asserted-by":"publisher","first-page":"11603","DOI":"10.1073\/pnas.0704409104","article-title":"Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4","volume":"104","author":"Bah","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111818085465100_B13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1124\/pr.111.004747","article-title":"Cofactoring and dimerization of proteinase-activated receptors","volume":"65","author":"Lin","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"2021111818085465100_B14","doi-asserted-by":"publisher","first-page":"16435","DOI":"10.1074\/jbc.270.27.16435","article-title":"Determinants of thrombin receptor cleavage. Receptor domains involved, specificity, and role of the P3 aspartate","volume":"270","author":"Ishii","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature11701","article-title":"High-resolution crystal structure of human protease-activated receptor 1","volume":"492","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"2021111818085465100_B16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1469-7793.2000.00319.x","article-title":"Desensitisation of protease-activated receptor-1 (PAR-1) in rat astrocytes: evidence for a novel mechanism for terminating Ca2+ signalling evoked by the tethered ligand","volume":"525","author":"Ubl","year":"2000","journal-title":"J. Physiol."},{"key":"2021111818085465100_B17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1139\/y97-110","article-title":"Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides","volume":"75","author":"Hollenberg","year":"1997","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"2021111818085465100_B18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.105.574830","article-title":"Protease-activated receptors in cardiovascular diseases","volume":"114","author":"Leger","year":"2006","journal-title":"Circulation"},{"key":"2021111818085465100_B19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3892\/ol.2011.291","article-title":"Protease-activated receptors in cancer: a systematic review","volume":"2","author":"Han","year":"2011","journal-title":"Oncol. Lett."},{"key":"2021111818085465100_B20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.coph.2007.01.002","article-title":"The therapeutic potential of proteinase-activated receptors in arthritis","volume":"7","author":"McIntosh","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"2021111818085465100_B21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1124\/jpet.108.145664","article-title":"Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis","volume":"328","author":"Zania","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021111818085465100_B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.59566\/IJBS.2014.10001","article-title":"Anti-parstatin promotes angiogenesis and ameliorates left ventricular dysfunction during pressure overload","volume":"10","author":"Givvimani","year":"2014","journal-title":"Int. J. Biomed. Sci."},{"key":"2021111818085465100_B23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000341871","article-title":"Parstatin prevents renal injury following ischemia\/reperfusion and radiocontrast administration","volume":"36","author":"Diamantopoulos","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"2021111818085465100_B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1478-811X-11-86","article-title":"Proteinase-activated receptors (PARs)\u2013focus on receptor-receptor-interactions and their physiological and pathophysiological impact","volume":"11","author":"Gieseler","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"2021111818085465100_B25","doi-asserted-by":"publisher","first-page":"e66743","DOI":"10.1371\/journal.pone.0066743","article-title":"Distinctive G protein-dependent signaling by protease-activated receptor 2 (PAR2) in smooth muscle: feedback inhibition of RhoA by cAMP-independent PKA","volume":"8","author":"Sriwai","year":"2013","journal-title":"PLoS One"},{"key":"2021111818085465100_B26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1124\/mol.109.062018","article-title":"PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology","volume":"77","author":"McCoy","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"2021111818085465100_B27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0031-6997(24)01493-5","article-title":"Proteinase-activated receptors","volume":"53","author":"Macfarlane","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"2021111818085465100_B28","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1073\/pnas.0700763104","article-title":"Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization","volume":"104","author":"McLaughlin","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111818085465100_B29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00018-008-7555-y","article-title":"The protease-activated receptor-3 (PAR-3) can signal autonomously to induce interleukin-8 release","volume":"65","author":"Ostrowska","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"2021111818085465100_B30","doi-asserted-by":"publisher","first-page":"20638","DOI":"10.1074\/jbc.M109.004762","article-title":"Thrombin promotes release of ATP from lung epithelial cells through coordinated activation of rho- and Ca2+-dependent signaling pathways","volume":"284","author":"Seminario-Vidal","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B31","doi-asserted-by":"publisher","first-page":"19728","DOI":"10.1074\/jbc.M909960199","article-title":"Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function","volume":"275","author":"Faruqi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B32","doi-asserted-by":"publisher","first-page":"26665","DOI":"10.1074\/jbc.M602174200","article-title":"PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation","volume":"281","author":"Holinstat","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B33","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1074\/jbc.M110.118018","article-title":"Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets","volume":"286","author":"Li","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B34","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1158\/1541-7786.514.2.9","article-title":"Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation","volume":"2","author":"Darmoul","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"2021111818085465100_B35","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/bph.12544","article-title":"Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease","volume":"171","author":"Hollenberg","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"2021111818085465100_B36","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1182\/blood-2012-08-452169","article-title":"Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46","volume":"120","author":"Mosnier","year":"2012","journal-title":"Blood"},{"key":"2021111818085465100_B37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1538-7836.2007.02500.x","article-title":"The central role of thrombin in hemostasis","volume":"5","author":"Crawley","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"2021111818085465100_B38","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/29325","article-title":"A dual thrombin receptor system for platelet activation","volume":"394","author":"Kahn","year":"1998","journal-title":"Nature"},{"key":"2021111818085465100_B39","doi-asserted-by":"publisher","first-page":"25216","DOI":"10.1074\/jbc.M004589200","article-title":"Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin","volume":"275","author":"Shapiro","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B40","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1124\/mol.106.033365","article-title":"PAR1, but not PAR4, activates human platelets through a Gi\/o\/phosphoinositide-3 kinase signaling axis","volume":"71","author":"Voss","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"2021111818085465100_B41","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein-coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ. Res."},{"key":"2021111818085465100_B42","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1182\/blood-2002-05-1470","article-title":"Protection against thrombosis in mice lacking PAR3","volume":"100","author":"Weiss","year":"2002","journal-title":"Blood"},{"key":"2021111818085465100_B43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2021111818085465100_B44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejphar.2015.05.046","article-title":"In\u00a0vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist","volume":"762","author":"Hawes","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"2021111818085465100_B45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00228-011-1120-6","article-title":"Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2021111818085465100_B46","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1074\/jbc.R112.355461","article-title":"Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development","volume":"287","author":"O'Callaghan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B47","doi-asserted-by":"publisher","first-page":"15785","DOI":"10.1074\/jbc.M115.636316","article-title":"Allosteric activation of a G protein-coupled receptor with cell-penetrating receptor mimetics","volume":"290","author":"Zhang","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2021111818085465100_B48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.112.091918","article-title":"Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin","volume":"126","author":"Zhang","year":"2012","journal-title":"Circulation"},{"key":"2021111818085465100_B49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/ATVBAHA.115.306777","article-title":"Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease","volume":"36","author":"Gurbel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111818085465100_B50","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2014-09-599910","article-title":"Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar","volume":"125","author":"Aisiku","year":"2015","journal-title":"Blood"},{"key":"2021111818085465100_B51","doi-asserted-by":"publisher","first-page":"e65528","DOI":"10.1371\/journal.pone.0065528","article-title":"Synthesis of indole derived protease-activated receptor 4 antagonists and characterization in human platelets","volume":"8","author":"Young","year":"2013","journal-title":"PLoS One"},{"key":"2021111818085465100_B52","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1182\/blood-2014-04-572479","article-title":"Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race","volume":"124","author":"Edelstein","year":"2014","journal-title":"Blood"}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/44\/2\/606\/432245\/bst0440606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/44\/2\/606\/432245\/bst0440606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:51:55Z","timestamp":1748865115000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/44\/2\/606\/67428\/Proteinase-activated-receptors-PARs-as-targets-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,11]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,4,11]]},"published-print":{"date-parts":[[2016,4,15]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20150282","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,11]]}}}